Statistics on Biotechnology Use  
Results by fields of operation
Total Sectors. Biotechnology indicators by execution sector.
Unidades: 

,Total 2021,Companies,P.A.,Higher Education,PNPI,
Companies that perform R+D in Biotechnology,1.498,1.299,120,66,13,
%Companies according to biotechnology used: Genetic code,38,30,8,87,5,89,4,46,2,
%Companies according to biotechnology used: Functional Companies,45,38,4,88,3,93,9,53,8,
%Companies according to biotechnology used: Cellular and tissue culturing and engineering,28,9,21,5,73,3,86,4,61,5,
%Companies according to biotechnology used: Bioprocesses,53,4,50,8,58,3,93,9,69,2,
%Companies according to biotechnology used: Sub-cellular organisms,15,2,8,5,53,3,74,2,38,5,
%Companies according to biotechnology used: Bio-computing,30,8,24,73,3,87,9,30,8,
%Companies according to biotechnology used: Nanobiotechnology,18,2,12,1,54,2,72,7,15,4,
%Companies according to biotechnology used: Other,15,3,16,9,3,3,7,6,0,
Companies in which biotechnology activities are:  Main and/or exclusive,603,559,31,3,10,
Companies in which biotechnology activities are: A secondary line of business,318,230,41,46,1,
Companies in which biotechnology activities are: A tool necessary for production,577,510,48,17,2,
%Companies by field(s) of ultimate application of biotechnology use: Human health,50,4,45,5,76,7,95,5,69,2,
%Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture,18,1,15,5,17,5,69,7,23,1,
%Companies by field(s) of ultimate application of biotechnology use: Food products,33,6,32,3,24,2,81,8,7,7,
%Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production,25,8,23,8,22,5,72,7,23,1,
%Companies by field(s) of ultimate application of biotechnology use: Environment,19,1,15,6,25,8,78,8,7,7,
%Companies by field(s) of ultimate application of biotechnology use: Industry,16,1,13,7,14,2,68,2,7,7,
Personnel in R&D in biotechnology (no. of persons),47.150,15.750,15.418,15.757,225,
Personnel in R&D in biotechnology (no. of persons): Research personnel,30.817,8.379,9.510,12.778,150,
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel,16.333,7.371,5.908,2.979,75,
Personnel in R&D in biotechnology (no. of persons). Women,26.632,8.711,9.684,8.101,136,
Personnel in R&D in biotechnology (no. of persons). Women. Research personnel,16.540,4.510,5.637,6.314,79,
Personnel in R&D in biotechnology (no. of persons). Women. Technical and auxiliary personnel,10.091,4.200,4.047,1.787,57,
Personnel in R&D in biotechnology (FTE),32.901,7,11.528,6,11.271,7,9.934,5,166,9,
Personnel in R&D in biotechnology (FTE): Research personnel,20.945,8,6.342,7,6.454,3,8.036,112,8,
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel,11.955,9,5.185,9,4.817,4,1.898,5,54,1,
Personnel in R&D in biotechnology (FTE). Women,18.952,5,6.539,7,7.077,3,5.228,107,5,
Personnel in R&D in biotechnology (FTE). Women: Research personnel,11.337,3,3.455,7,3.786,8,4.032,9,61,9,
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel,7.615,2,3.084,3.290,5,1.195,1,45,6,
Internal expenditure on R&D (thousands of euros),2.269.946,1.038.582,716.877,500.703,13.783,
1) By nature of the expense: Current expenses,2.087.088,940.091,672.607,461.216,13.174,
1.1) Remuneration to research personnel,872.195,321.570,252.863,293.131,4.630,
1.2) Remuneration to technicians and auxiliary personnel,384.422,194.836,128.640,59.408,1.538,
1.3) Other current expenses,830.471,423.685,291.103,108.677,7.006,
2) By nature of the expense: Capital expenses,182.858,98.492,44.270,39.487,610,
2.1) Land and buildings,20.307,10.199,2.712,7.373,23,
2.2) Equipment and instruments,144.143,72.584,40.235,30.775,549,
2.3) Acquisition of specific R+D software,8.159,5.721,1.102,1.303,33,
2.4) Otros productos de propiedad intelectual específicos para I+D,10.250,9.987,222,36,5,
1.1) By origin of the funds: Own funds,891.566,711.488,88.338,88.167,3.574,
1.2) By origin of the funds: From companies,248.128,121.738,97.993,25.096,3.301,
1.3) By origin of the funds: Public Administration funds,882.585,107.477,430.689,342.018,2.402,
1.4) By origin of the funds: From Universities,3.851,192,1.388,2.220,50,
1.5) By origin of the funds: From non profit private institutions,47.810,10.756,26.599,7.719,2.737,
1.6) By origin of the funds: Foreign funds,196.006,86.931,71.871,35.483,1.720,
Purchase of services R & D in Biotechnology to (thousands of euros),174.934,145.557,23.461,3.058,2.858,
Purchase of services R & D in Biotechnology to (thousands of euros): in Spain,123.461,95.915,21.807,3.035,2.704,
Purchase of services R & D in Biotechnology to (thousands of euros): Abroad,51.472,49.642,1.654,23,154,
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital,43,40,2,63,3,57,6,61,5,
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information,12,5,13,2,6,7,9,1,15,4,
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources,22,1,19,45,40,9,23,1,
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain,13,6,11,5,26,7,33,3,7,7,
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets,18,2,15,9,30,42,4,15,4,
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels,18,9,17,27,5,39,4,30,8,
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception,15,9,16,4,10,12,1,30,8,
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements,40,5,40,5,40,37,9,61,5,
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost,55,4,55,58,3,57,6,61,5,
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting,21,9,21,9,24,2,18,2,23,1,
Notas:
'..'=data not available 

 '.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent 

 (*) Total calculated from the total number of companies with related activities  with Biotechnology and the total Companies from other sectors with activities  in R&D in Biotechnology
Fuente: National Statistics Institute